Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab plus lenvatinib first-line study in unresectable or metastatic hepatocellular carcinoma
ChiCTR2100054077Phase 4Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Nov 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of zimberelimab and lenvatinib in hepatocellular carcinoma (HCC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Started Nov 2021; status: recruiting.
02
Drugs
zimberelimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100054077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054077.